Emergen Research, a globally recognized provider of market research and business intelligence solutions, has released a detailed analysis of the global Novel Drug Delivery System Market, highlighting the major trends, technological developments, growth drivers, market challenges, and emerging opportunities shaping the pharmaceutical and biopharmaceutical industries.

Novel drug delivery systems are transforming the way medicines are formulated, administered, and absorbed by patients. Advances in delivery technologies are allowing pharmaceutical companies to move beyond conventional administration methods and develop treatments that can improve dosing convenience, reduce administration frequency, enhance therapeutic performance, and support more patient-centric models of care.

The global Novel Drug Delivery System Market was valued at USD 38.50 Billion in 2025 and is projected to reach USD 117.95 Billion by 2035, expanding at a CAGR of 11.8% from 2026 to 2035. The market is expected to grow from USD 43.20 Billion in 2026. North America accounted for the largest revenue share of 46.2% in 2025, supported by strong biopharmaceutical activity, advanced healthcare infrastructure, and widespread adoption of delivery-enabled biologic therapies.

The market is being driven by the conversion of intravenous therapies into subcutaneous formulations, increasing adoption of long-acting injectable medicines, rapid development of lipid nanoparticle delivery technologies, and growing licensing activity around proprietary drug delivery platforms.

Request Free Sample Copy (To Understand the Complete Structure of this Report [Summary + TOC]) @ https://www.emergenresearch.com/request-free-sample/220502

A sample of the report provides an overview of the market structure, key growth trends, technology developments, major segments, regional opportunities, and competitive landscape covered in the study.

Key Trends Shaping the Novel Drug Delivery System Market

One of the most important developments in the market is the growing conversion of intravenous therapies into subcutaneous formulations. Intravenous medicines often require administration by healthcare professionals in hospitals, infusion centers, or specialized clinics. This can increase treatment time and create additional demands on healthcare facilities.

Subcutaneous delivery technologies can provide an alternative by enabling certain high-volume biologic therapies to be administered through shorter injections. In some cases, these treatments can also be administered by patients themselves at home. This can reduce the dependence on infusion-center infrastructure while providing greater flexibility for patients receiving long-term treatment.

Drug delivery technology companies are therefore working closely with biopharmaceutical manufacturers to convert established intravenous medicines into more convenient subcutaneous products. Such collaborations are creating additional commercial opportunities for companies that own proprietary delivery platforms.

Long-acting injectable formulations are another important growth area. These products are designed to release active pharmaceutical ingredients gradually over an extended period, reducing the frequency with which patients need to receive a dose. For chronic diseases requiring long-term treatment, reducing daily or frequent dosing can help simplify treatment schedules and support continued therapy.

Lipid nanoparticle technology has also gained considerable attention following its role in mRNA vaccine development. Lipid nanoparticles protect fragile nucleic acid payloads and help transport them into cells, creating opportunities for applications extending beyond vaccines into RNA-based therapeutics, gene-editing technologies, and other advanced treatments.

The continued licensing of proprietary delivery platforms is further supporting market expansion. Biopharmaceutical companies can use established delivery technologies to differentiate products, improve administration convenience, and extend the commercial potential of existing molecules.

Market Drivers

The increasing conversion of intravenous biologic therapies into subcutaneous formulations is one of the strongest drivers of the market. Large biologic molecules have historically required intravenous administration because of their formulation characteristics and delivery limitations. Novel delivery technologies are helping companies overcome some of these limitations and develop more convenient administration options.

The commercial performance of delivery-platform developers demonstrates the potential of this trend. Halozyme Therapeutics reported record full-year 2025 revenue of USD 1.40 Billion, while royalty revenue reached USD 868.0 Million, reflecting strong contributions from products using its ENHANZE delivery platform.

Long-acting injectable technologies are also gaining traction as pharmaceutical companies look for ways to reduce treatment frequency. Instead of requiring patients to take medication every day or receive frequent injections, long-acting formulations can maintain therapeutic drug concentrations over longer periods.

This approach is particularly relevant to chronic conditions where treatment adherence can affect outcomes. By reducing the number of dosing decisions a patient needs to make, long-acting formulations can make treatment schedules easier to manage.

Another important driver is the expansion of lipid nanoparticle delivery. The successful use of lipid nanoparticles in mRNA vaccines demonstrated that these systems can protect delicate genetic payloads and facilitate their delivery into cells. Pharmaceutical and biotechnology companies are now exploring similar approaches for a broader range of therapeutic applications.

Licensing and collaboration activity is also contributing to market growth. Biopharmaceutical companies can gain access to specialized delivery technologies without having to develop the entire platform internally, creating a business model in which technology developers generate licensing and royalty revenue from successful partner products.

Market Restraints

Despite the strong growth outlook, novel drug delivery technologies face several challenges. Developing a new formulation or converting an established medicine to a different delivery platform can require significant research, development, clinical testing, and regulatory investment.

A pharmaceutical company cannot necessarily transfer an existing approved product to a new delivery system without additional development work. The reformulated product may need to demonstrate comparable clinical performance, bioequivalence, safety, or other regulatory requirements before commercialization.

Patent and exclusivity considerations can also influence the economics of delivery platforms. When the underlying medicine approaches generic or biosimilar competition, royalty streams associated with a delivery technology may also face pressure if the commercial sales of the branded product decline.

Supply-chain costs represent another consideration. Novel delivery systems can depend on specialized lipids, polymers, enzymes, device components, and other materials. Changes in freight costs, raw-material prices, and international supply conditions can therefore affect manufacturing economics.

Regulatory Landscape

Novel drug delivery systems are generally regulated as part of the pharmaceutical or biologic product they are designed to deliver. When an existing medicine is reformulated using a new delivery technology, manufacturers may need to provide additional evidence demonstrating that the new formulation delivers the intended therapeutic effect safely and consistently.

In the United States, the Food and Drug Administration evaluates delivery-enabled products through applicable drug and biologics approval pathways. Some delivery systems, such as prefilled autoinjectors and on-body delivery devices, may also involve combination-product considerations because they incorporate both a medicinal product and a device component.

In Europe, novel delivery products are subject to the applicable regulatory framework for medicinal products and, where relevant, medical-device requirements. Regulatory requirements can vary depending on the characteristics of the delivery system and how it is integrated with the underlying pharmaceutical product.

Other major pharmaceutical markets, including Japan and China, maintain their own regulatory pathways for novel formulations and delivery technologies. As delivery platforms expand internationally, developers must therefore navigate regulatory requirements across multiple jurisdictions.

Value Chain Analysis

The value chain for novel drug delivery systems begins with suppliers of specialized materials and components. These include lipids, polymers, enzymes, device components, and other materials required to manufacture advanced delivery systems.

Delivery technology developers then design and commercialize proprietary platforms that can be licensed to pharmaceutical and biotechnology companies. In other cases, biopharmaceutical companies develop delivery technologies internally and integrate them into their own drug-development programs.

Specialized companies such as Halozyme Therapeutics, Ypsomed, and Enable Injections participate in different parts of this ecosystem, providing technologies or devices that can improve the administration of pharmaceutical products.

The final stage involves distribution and administration through hospitals, clinics, specialty pharmacies, healthcare providers, and increasingly home-based treatment settings. The commercial value of a novel delivery system ultimately depends on whether it provides meaningful benefits in terms of convenience, dosing frequency, administration time, or treatment accessibility.

Novel Drug Delivery System Market Segmentation

By Technology

The market is segmented into Subcutaneous Delivery Enhancement, Long-Acting Injectables, Lipid Nanoparticle Delivery, and Others.

The Subcutaneous Delivery Enhancement segment accounted for 34.6% of the global market in 2025, representing the largest technology segment.

Subcutaneous delivery enhancement technologies allow certain high-volume or complex biologic medicines to be administered through the subcutaneous route. This can help convert products that traditionally required intravenous infusion into more convenient injection-based therapies.

The commercial opportunity is particularly significant for monoclonal antibodies and other biologic medicines because many of these therapies have historically depended on infusion-center administration.

Long-acting injectables address a different challenge by extending the duration over which a medicine remains therapeutically active. These products can reduce the frequency of treatment and support simplified dosing schedules for patients with chronic conditions.

The Lipid Nanoparticle Delivery segment is projected to register a CAGR of 15.6% through 2035. Its growth is being supported by the expansion of RNA-based therapeutics and other advanced pharmaceutical applications that require efficient intracellular delivery.

Lipid nanoparticles provide a protective structure around sensitive genetic payloads and help transport them into target cells. The technology therefore has potential applications in areas extending beyond the vaccine market.

Other delivery technologies include emerging systems such as microneedles, implants, and specialized formulation technologies designed to address specific administration and drug-release requirements.

By Route of Administration

Based on route of administration, the global market is divided into Parenteral, Oral, Transdermal, and Others.

The Parenteral segment held 48.2% of the global market share in 2025, making it the largest segment.

Parenteral delivery includes subcutaneous and intramuscular administration methods and remains particularly important for biologic medicines. Many large biological molecules cannot be administered effectively through the gastrointestinal tract, making injectable routes essential.

The continued development of subcutaneous delivery technologies is creating opportunities to move certain treatments away from intravenous infusion toward shorter and potentially self-administered injections.

The Transdermal segment is expected to expand at a CAGR of 13.2% through 2035. Transdermal systems can deliver medicines through the skin using patches or advanced microneedle technologies.

This approach can provide controlled drug release while avoiding some of the challenges associated with traditional injections. Microneedle-based systems are receiving increasing attention because they can create microscopic pathways through the skin while minimizing the discomfort associated with conventional needles.

Oral delivery remains important for suitable small-molecule drugs, while other administration routes such as intranasal and inhaled delivery address specific therapeutic requirements.

By Application

Based on application, the market is segmented into Oncology, Autoimmune & Inflammatory Diseases, Neurology, and Others.

The Oncology segment accounted for 36.8% of the global market in 2025, representing the largest application segment.

Cancer treatment has become an important area for novel drug delivery because many oncology therapies are complex biologic medicines that traditionally require intravenous administration. Subcutaneous conversion can provide patients with shorter administration times and, where appropriate, greater flexibility in receiving treatment.

Novel delivery systems are also being explored for targeted and controlled drug release in cancer treatment. These technologies can potentially improve the delivery of therapeutic molecules while reducing unnecessary exposure to healthy tissues.

The Neurology segment is expected to register a CAGR of 14.4% through 2035. Growing development of biologic treatments for neurological and neuromuscular conditions is creating opportunities for delivery technologies that can simplify treatment administration.

Patients with neurological conditions may face additional challenges associated with frequent hospital or infusion-center visits. As a result, delivery systems that reduce administration frequency or enable more convenient treatment could become increasingly relevant.

Autoimmune and inflammatory diseases also represent an important application area because several biologic therapies used in these conditions are being developed or reformulated for subcutaneous administration.

By End User

The market is segmented into Biopharmaceutical Companies, Hospitals & Clinics, and Others.

The Biopharmaceutical Companies segment held 58.4% of the global market share in 2025, representing the largest end-user category.

Biopharmaceutical companies are the primary adopters and commercial partners for many novel drug delivery technologies. These companies can license proprietary platforms or develop internal delivery capabilities to improve existing products and differentiate new therapies.

Delivery technology can also help pharmaceutical companies extend the commercial potential of established products by providing an alternative administration method.

The Hospitals & Clinics segment is projected to register a CAGR of 12.6% through 2035. Hospitals and clinics remain important because many biologic and specialty treatments still require healthcare-provider administration.

As delivery technologies enable shorter administration times and greater use of outpatient treatment, healthcare facilities may increasingly incorporate delivery-enabled products into their treatment workflows.

Home healthcare providers and patients represent another emerging end-user category as more products become suitable for self-administration outside traditional clinical settings.

Custom Requirements can be requested for this Report [Customization Available] @ https://www.emergenresearch.com/request-for-customization/220502

Regional Outlook

North America accounted for the largest share of the global market, representing 46.2% of revenue in 2025. The region benefits from a strong concentration of pharmaceutical and biotechnology companies, advanced healthcare infrastructure, significant investment in drug development, and early adoption of innovative biologic therapies.

The United States led the North American market in 2025. The presence of major biopharmaceutical companies and specialized delivery technology developers has created a strong ecosystem for licensing, development, and commercialization of novel delivery platforms.

Europe is projected to grow at a CAGR of 10.4% through 2035. The region represented approximately 27.6% of the global market in 2025 and benefits from an established pharmaceutical industry and regulatory infrastructure.

Asia Pacific is projected to register the fastest CAGR of 15.2% through 2035. The region accounted for 18.4% of the global market in 2025. Increasing biopharmaceutical manufacturing capacity and expanding domestic pharmaceutical development in countries such as China, Japan, and South Korea are supporting market growth.

Latin America is projected to grow at a CAGR of 9.6% through 2035. Brazil and Mexico represent important pharmaceutical markets in the region, while increasing access to biologic treatments is creating additional opportunities for delivery-enabled therapies.

The Middle East & Africa market is projected to expand at a CAGR of 9.1% through 2035. Healthcare infrastructure investment and growing access to advanced pharmaceutical treatments are supporting demand, particularly in countries with developed healthcare systems.

Novel Drug Delivery System Market Competitive Landscape

The global Novel Drug Delivery System market is moderately fragmented, with established pharmaceutical technology companies, delivery-platform developers, device manufacturers, and specialized biotechnology companies participating across different technology categories.

Companies are focusing on strategic collaborations, licensing agreements, acquisitions, platform development, formulation technologies, and device innovation to expand their presence in the market.

Major companies included in the global Novel Drug Delivery System market are:

The competitive environment is increasingly influenced by the ability of companies to provide delivery platforms that can be integrated efficiently with high-value pharmaceutical products while meeting clinical and regulatory requirements.

Industry Developments

Recent developments demonstrate the increasing commercial importance of novel drug delivery technologies.

In February 2026, Halozyme Therapeutics reported full-year 2025 results showing total revenue of USD 1.40 Billion, representing a 38% year-over-year increase. The company's royalty revenue reached USD 868.0 Million, with growth attributed to ENHANZE-enabled products including DARZALEX SC, Phesgo, and VYVGART Hytrulo.

In December 2025, Halozyme completed its acquisition of Surf Bio, adding hyperconcentration formulation technology to its existing drug delivery portfolio. The acquisition expanded the company's capabilities beyond its ENHANZE platform.

In August 2026, Halozyme reported second-quarter 2026 revenue of USD 481.0 Million, representing a 48% year-over-year increase. The company also reported five new ENHANZE and Hypercon collaboration agreements during the year-to-date period with biopharmaceutical partners including Vertex, Oruka, GSK, and Incyte.

These developments highlight the continued use of partnerships, acquisitions, and licensing arrangements to expand novel drug delivery technology portfolios.

Future Outlook

The Novel Drug Delivery System Market is expected to remain an important part of pharmaceutical innovation as companies increasingly focus on improving treatment convenience, administration flexibility, dosing frequency, and patient experience.

The conversion of intravenous biologics into subcutaneous formulations is expected to remain a significant source of demand, particularly for high-value therapies used in oncology, autoimmune diseases, and other chronic conditions.

Long-acting injectable technologies are also expected to gain further adoption as pharmaceutical companies seek to reduce dosing frequency and simplify treatment schedules. At the same time, lipid nanoparticle platforms could open new opportunities across RNA therapeutics, gene-editing technologies, and other advanced treatments.

Asia Pacific is expected to experience the fastest regional expansion, while North America is expected to remain an important market because of its established biopharmaceutical ecosystem and strong adoption of advanced delivery technologies.

The global Novel Drug Delivery System Market, valued at USD 38.50 Billion in 2025, is projected to reach USD 117.95 Billion by 2035, registering a CAGR of 11.8% during 2026–2035. Continued pharmaceutical innovation, growing demand for patient-friendly administration methods, and expanding investment in advanced delivery platforms are expected to support market growth throughout the forecast period.

Organizations requiring specific market segments, regional analysis, competitive intelligence, technology-level insights, or application-specific information can request a customized version of the study based on their business requirements.

The complete Novel Drug Delivery System Market report provides detailed analysis of market size, technology trends, route of administration, applications, end users, regional performance, competitive developments, and future growth opportunities through 2035.

Browse Full Report Description + Research Methodology + Table of Content + Infographics @ https://www.emergenresearch.com/industry-report/novel-drug-delivery-system-market

About Emergen Research

Emergen Research is a market research and consulting company providing syndicated and customized research reports across multiple industries. The company offers market intelligence, industry analysis, competitive benchmarking, strategic consulting, and customized research solutions to help businesses understand changing market conditions and identify emerging opportunities.

Contact Us:

Eric Lee

Corporate Sales Specialist

Emergen Research | Web: https://www.emergenresearch.com/

Direct Line: +1 (604) 757-9756

E-mail: [email protected]


Google AdSense Ad (Box)

Comments